Summary: NBC News Bay Area reports on the Drug Enforcement Administration (DEA)’s March 13 approval of MAPS’ upcoming clinical study of MDMA as an adjunct to psychotherapy for people diagnosed with anxiety associated with life-threatening illness. The article notes that MAPS’ growing psychedelic research program has received DEA approval for seven MDMA studies, and invites readers to attend "Psychedelic Experience: New Uses and Research," MAPS’ upcoming educational event taking place at Sofia University in Palo Alto on April 17, 2015.
Originally appearing here.
The Drug Enforcement Agency has approved a Bay Area nonprofit to study the impact of using Ecstasy to treat terminally ill patients.
Santa Cruz’s Multidisciplinary Association for Psychedelic Studies (MAPS) will start a clinical trial to study a combination of pure MDMA and therapy to treat anxiety for 18 end-of-life patients. MAPS has now been approved for seven separate studies of MDMA, more than any other organization; the majority of them focus on treating patients with Post Traumatic Stress Disorder.
"They’ve been approved for all studies before, but the latest nod seems indicative of a shift in the DEA’s stand on the dangers of the drug," reports Engadget.
MAPS researches possible beneficial applications of several psychedelic substances. The organization will present a public program called "Psychedelic Experience: New Uses and Research" at Sofia University in Palo Alto on April 17.
